Biotechnologist

PhD Student

2014:Bachelor’s Degree in Biotechnology  University of L’Aquila, final mark: 109/110

2017: Master Degree in Molecular and Industrial Biotechnology at the University of Bologna, 110/110 cum Laude

• 2023-present: Researcher in Health at Laboratorio di Oncologia Sperimentale 
• 2020-present: PhD Student (Oncology, Hematology and Pathology Unibo) at Experimental Oncology Lab of Rizzoli Institute, Bologna.
• May 2020-April 2023: Fellowship at Experimental Oncology Lab of Rizzoli Institute, Bologna.
• May 2018 – Septrember 2019: Technician at Janssen-Pharmaceutical Companies of Jhonson & Jhonson (Latina)
• August 2017- May 2018: Pharmaceutical and validation consultant at SGS sertec Srl (Bologna).

Italian: mother tongue
English: B2

• HPLC and UPLC, Dissolution test, Karl Fischer, NIR, IR, TLC, UV
• Data analysis programs: Empower, Nugenesis, Lims
• IT tool: Excel, Word, Power Point, Open Office, SPSS, Latex, SAP
• Molecular Biology techniques: RNA extraction and quantification; PCR; Real Time PCR; protein extraction; Western Blotting; RNA immunoprecipitation assay
• Cell culture techniques: manage of human tumoral cells; transfection techniques; soft-Agar; Motility Test; Homotipic aggregation; Wound healing assay
• Immunohistochemistry; Immunofluorescence on fixed and non fixed cells, citofluorimetric analisys (FACS).

Accelerating Biomarkers and targeted therapy development in metastatic Ewing Sarcomas: Focus on cell plasticity.

• “CIC-Rearranged Sarcomas: An Intriguing Entity That May Lead the Way to the Comprehension of More Common Cancers”. Cancers (Basel). 2022 Link: https://doi.org/10.3390/cancers14215411
• “Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma”, Cancer Research, 2022 Link: https://doi.org/10.1158/0008-5472.CAN-21-1222
• “Insulin like growth factor 2 mRNA-binding protein 3 influences sebsitivity to anti-IGF system agents through the translationalregulation of IGF1R”, Frontiers in Endocrinology, section Cancer Endocrinology,2018 Link: https://doi.org/10.3389/fenso.2018.00178
• “Insulin like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing Sarcoma Malignancy”, Clinical Cancer Research,2018 Link: https://doi.org/10.1558/1078-0432.CCR-17-2602.

Oncologic Research, Ewing sarcoma, Osteosarcoma, IGF2BP3, BET inhibitor.